Moderna, Inc. Common Stock (MRNA) Financial Statements
Historical financial data — 30 statements covering FY2018–FY2025
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which w...
Moderna, Inc. Common Stock's revenue decreased 39.9% year over year, from $3.24B to $1.94B.
Net income increased 20.8% over the same period, from $-3.56B to $-2.82B.
Over the 7-year period from FY2018 to FY2025, revenue grew by 1339% in total.
The debt-to-equity ratio stands at 0.07, indicating a conservative leverage profile.
Operating cash flow grew 37.6% to $-1.87B.
Moderna, Inc. Common Stock maintains a negative net profit margin of -145.2%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $4.04B+83.0% | $-4.93B | $273.0M | $-4.25B | $-3.74B | $19.45B | N/A | $13.46B |
| Q1 FY2024 | $167.0M-95.9% | $-1.18B | $71.0M | $-1.27B | $-989.0M | $16.73B | N/A | $12.82B |
| Q2 FY2024 | $408.0M+144.3% | $-2.45B | $197.0M | $-2.63B | $-2.26B | $15.68B | N/A | $11.71B |
| Q3 FY2024 | $2.27B+456.4% | $-2.44B | $1.54B | $-2.70B | $-3.83B | $15.80B | N/A | $11.93B |
| Q1 FY2025 | $108.0M-95.2% | $-971.0M | $18.0M | $-1.05B | $-1.04B | $12.70B | N/A | $10.07B |
| Q2 FY2025 | $250.0M+131.5% | $-1.80B | $41.0M | $-1.96B | $-1.96B | $12.01B | N/A | $9.40B |
| Q3 FY2025 | $1.27B+406.4% | $-2.00B | $850.0M | $-2.22B | $-2.80B | $12.13B | N/A | $9.33B |
| Q1 FY2026 | $389.0M-69.3% | $-1.34B | $-566.0M | $-1.39B | $-630.0M | $11.49B | $590.0M | $7.41B |
Balance Sheet Summary (Latest Period)
Total Assets
$12.34B
Total Liabilities
$3.69B
Total Equity
$8.65B
Cash & Equivalents
$5.80B
Total Debt
$590.0M
Current Assets
$6.54B
Current Liabilities
$1.99B
Retained Earnings
$7.22B